Kymera Results Presentation Deck

* Maximum % Change from Baseline -20 - -40- -60 - -80 -100 - HV (MAD3) Up to 98% Inhibition of 9 Disease-Relevant Cytokines Ex Vivo in both HS and AD Patients |'||||| peppe IFNY IL10 IL12 IL17 IL1b IL23 IL6 IL8 TNFa -67% -45% -47% -20% -64% -54% AD -95% -98% -76% KYMERA LPS HS -36% -52% -84% -8% -44% -31% -50% -59% -57% -49% -60% -83% -63% -95% -70% -85% -74% Ⓒ2022 KYMERA THERAPEUTICS, INC. -41% MAD 3 Healthy Subjects 100 mg QD (n = 9) Part C AD Patients (n=7) Plots show median of the maximum change from baseline between Days 7-14 in MAD3, and Days 14-28 in Part C Part C HS Patients (n=9) Maximum % Change from Baseline -20- -40- -60- -80- -100- HV (MAD3) AD HS IFNY IL10 IL12 IL17 IL1b -87% -95% -76% -50% -71% -55% -67% -64% 0% -72% IL6 -54% -81% -74% -35% -69% -46% -57% -50% IL8 -33% -48% -43% R848 TNFa -62% -62% -54% PAGE 40

View entire presentation